Study Title: A Phase I, First-in-human, Open-label, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BNT317 in Patients With Advanced Solid Tumors
For more information about the trial above please contact the study team:Medical University of South CarolinaPrincipal Investigator, Kaczmar, John, at kaczmar@musc.edu, or please call +1 843-792-6691.Study Coordinator, Boggan, Holly, at bogganhl@musc.edu, or please call +1 843-792-8068.Trial opened at the following institutions: Medical University of South Carolina